Cargando…
(−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer
(−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas. To improve the pharmacological profile of EGCG, we previously de...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099607/ https://www.ncbi.nlm.nih.gov/pubmed/29751678 http://dx.doi.org/10.3390/molecules23051160 |
_version_ | 1783348704438124544 |
---|---|
author | Crous-Masó, Joan Palomeras, Sònia Relat, Joana Camó, Cristina Martínez-Garza, Úrsula Planas, Marta Feliu, Lidia Puig, Teresa |
author_facet | Crous-Masó, Joan Palomeras, Sònia Relat, Joana Camó, Cristina Martínez-Garza, Úrsula Planas, Marta Feliu, Lidia Puig, Teresa |
author_sort | Crous-Masó, Joan |
collection | PubMed |
description | (−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas. To improve the pharmacological profile of EGCG, we previously developed a family of EGCG derivatives and the lead compounds G28, G37 and G56 were characterized in HER2-positive breast cancer cells overexpressing FASN. Here, diesters G28, G37 and G56 and two G28 derivatives, monoesters M1 and M2, were synthesized and assessed in vitro for their cytotoxic, FASN inhibition and apoptotic activities in MDA-MB-231 triple-negative breast cancer (TNBC) cells. All compounds displayed moderate to high cytotoxicity and significantly blocked FASN activity, monoesters M1 and M2 being more potent inhibitors than diesters. Interestingly, G28, M1, and M2 also diminished FASN protein expression levels, but only monoesters M1 and M2 induced apoptosis. Our results indicate that FASN inhibition by such polyphenolic compounds could be a new strategy in TNBC treatment, and highlight the potential anticancer activities of monoesters. Thus, G28, G37, G56, and most importantly M1 and M2, are anticancer candidates (alone or in combination) to be further characterized in vitro and in vivo. |
format | Online Article Text |
id | pubmed-6099607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60996072018-11-13 (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer Crous-Masó, Joan Palomeras, Sònia Relat, Joana Camó, Cristina Martínez-Garza, Úrsula Planas, Marta Feliu, Lidia Puig, Teresa Molecules Article (−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas. To improve the pharmacological profile of EGCG, we previously developed a family of EGCG derivatives and the lead compounds G28, G37 and G56 were characterized in HER2-positive breast cancer cells overexpressing FASN. Here, diesters G28, G37 and G56 and two G28 derivatives, monoesters M1 and M2, were synthesized and assessed in vitro for their cytotoxic, FASN inhibition and apoptotic activities in MDA-MB-231 triple-negative breast cancer (TNBC) cells. All compounds displayed moderate to high cytotoxicity and significantly blocked FASN activity, monoesters M1 and M2 being more potent inhibitors than diesters. Interestingly, G28, M1, and M2 also diminished FASN protein expression levels, but only monoesters M1 and M2 induced apoptosis. Our results indicate that FASN inhibition by such polyphenolic compounds could be a new strategy in TNBC treatment, and highlight the potential anticancer activities of monoesters. Thus, G28, G37, G56, and most importantly M1 and M2, are anticancer candidates (alone or in combination) to be further characterized in vitro and in vivo. MDPI 2018-05-11 /pmc/articles/PMC6099607/ /pubmed/29751678 http://dx.doi.org/10.3390/molecules23051160 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Crous-Masó, Joan Palomeras, Sònia Relat, Joana Camó, Cristina Martínez-Garza, Úrsula Planas, Marta Feliu, Lidia Puig, Teresa (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title | (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title_full | (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title_fullStr | (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title_full_unstemmed | (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title_short | (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer |
title_sort | (−)-epigallocatechin 3-gallate synthetic analogues inhibit fatty acid synthase and show anticancer activity in triple negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099607/ https://www.ncbi.nlm.nih.gov/pubmed/29751678 http://dx.doi.org/10.3390/molecules23051160 |
work_keys_str_mv | AT crousmasojoan epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT palomerassonia epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT relatjoana epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT camocristina epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT martinezgarzaursula epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT planasmarta epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT feliulidia epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer AT puigteresa epigallocatechin3gallatesyntheticanaloguesinhibitfattyacidsynthaseandshowanticanceractivityintriplenegativebreastcancer |